The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes.
The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength.
Participants will:
* Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing
Postmenopausal women aged 65 years or older
Has type 2 diabetes
Body Mass Index (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive)
Hemoglobin A1c >7% within 3 months of the first visit.
Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D
eGFR <30 ml/min in the last 3 months
Patients with a history of treatment with anti-osteoporosis agents
Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies
Emory University
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator